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Reducing health inequalities is a primary goal in public health [1]–[3]. Impact on health 
inequality should, therefore, be an important component in determining the value of 
investments in public health interventions.  However, public health commissioners, or the 
agencies that inform them with recommendations and guidelines, do not routinely undertake 
quantitative assessment of how interventions change health inequality. For example, the 
National Institute for Health and Care Excellence (NICE) produces evidence-based guidance 
for local commissioners in England [4]. The quantitative component of the value for money 
assessment is the amount of population health generated by an intervention, relative to its 
cost.  Whilst in some cases qualitative information is provided on health inequalities relevant 
to the decision problem, evidence on how inequality is expected to actually change is not 
provided. 
 
Distributional cost-effectiveness analysis (DCEA) is an approach to economic evaluation that 
considers population health and health inequality impacts simultaneously. Compared with 
standard economic evaluations that generate information on mean outcomes only, decision 
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analytic models in DCEAs use additional data to reflect social variation in the model inputs. 
This allows them to estimate the cumulative inequality impact of an intervention across the 
different stages of the course of disease and treatment, such as incidence, treatment uptake 
and adherence – the so-called ‘staircase effect’ [5]. The inequalities present at each staircase 
level can potentially compound or offset one another and can have vastly different effects on 
the overall inequality impact.  
 
The objective of this paper is to address two key questions relating to the feasibility and 
practicality of conducting DCEAs: (i) how existing decision analytic models can be 
retrospectively adapted using existing published evidence and (ii) how incorporating social 
variation at specific points in the course of disease and treatment can affect the cumulative 
inequality impact. These issues are explored through a pilot study to formally incorporate 
inequality in an appraisal of behavioural and pharmacological interventions for smoking 
cessation for the National Institute for Health and Care Excellence’s (NICE) public health 







Our analysis is divided into three stages.  Using the case study decision model (described 
below), we first identify evidence that describes how the model inputs vary by 
socioeconomic status. This produces a decision model that is able to estimate the incremental 
costs and health benefits for a recipient of each intervention from each socioeconomic 
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subgroup.  Next, the results per individual are scaled up to population level using estimates of 
the recipient population size and utilisation levels in each socioeconomic subgroup. The net 
population-level effects account for the health effects of alternative uses of resources (health 
opportunity costs), and how these forgone benefits are expected to be distributed between 
subgroups. 
 
In stage three the net health effects for each subgroup are then added to a corresponding 
estimate of baseline health. Population health and health inequality impacts are summarised 
graphically on the health equity impact plane [6].  If a dominant intervention is identified that 
provides the greatest increase in health and that reduces health inequality by the greatest 
amount, no further analysis is required.  Formal analysis of the trade-off between these two 
objectives is required when this is not the case. 
 
A range of scenario analyses explore how accounting for social variation in different sets of 
parameters affects our results.  We do this estimating the distribution of health benefits when 
accounting for only (i) smoking prevalence or (ii) prevalence and service utilisation. Both 
scenarios assume that per recipient health benefits and cost impact of each intervention is 
uniform over subgroups.    
 
Smoking cessation case study 
 
Smoking remains a significant cause of ill health and death worldwide, despite public health 
efforts and cigarette taxes [7]. In England, approximately 4 per cent of hospital admissions 
and 17 per cent of deaths are related to smoking [8]. Smoking and smoking-related disease 
increases with measures of social disadvantage: those with low incomes, less qualifications 
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and living in poor neighbourhoods are more likely to smoke. In Great Britain, 20 per cent of 
adults who earn less than £10,000 per year smoke compared to 10 percent of those who earn 
£40,000 and above [9]. Smoking therefore remains a key determinant of both health 
inequality and population health. 
 
NICE produced guidance for public health commissioners on the use of behavioural and 
pharmacological interventions to stimulate smoking cessation in 2018 [10].  The economic 
analysis indicated that these interventions increased health on average, and either saved costs 
or increased cost by less than £4,000 per quality-adjusted life year (QALY) gained.  
However, their impact on health inequality was not formally assessed.  While the health 
burden of smoking is highest among socioeconomically disadvantaged groups, individuals in 
the most advantaged groups are more likely to utilise smoking cessation services  [11], [12].  
This countervailing socioeconomic variation makes the net impact of providing smoking 
cessation services on health inequality hard to judge. Local authorities faced with the choice 
between smoking cessation interventions or something else, may desire information on which 
works best for disadvantaged groups. 
 
In this case study, we retrospectively adapt the decision model used in the 2018 guideline 
[10], [13] to conduct a DCEA of 21 behavioural and pharmacological smoking cessation 
interventions [14]–[24]. 
 
Decision model adaptation  
 
The original decision model was built to reflect a health sector (NHS) perspective, and 
estimated costs and quality adjusted life-years over a lifetime time horizon.  A cohort of 
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smokers enter the model (Figure 1), and transition to former smokers based on the 
effectiveness of interventions in supporting successful quit attempts (measured at one year). 
Mortality and disease risks depend on age and smoking status, with former smokers facing 
lower risks of developing any of the six smoking-related comorbidities and experiencing 
better health-related quality of life. All interventions are compared to a background annual 
quit rate of 2%, which represents smokers who naturally quit without intervention [25]. The 
model is run for cohorts of smokers of different ages, before the results are combined to 
calculate the weighted average costs and QALYs per smoker overall. 
 
Figure 1 Model structure for smoking cessation interventions 
 
Note: LC = lung cancer; CHD = coronary heart disease; MI = myocardial infarction; COPD = chronic 
obstructive pulmonary disease; asthma = asthma exacerbation. 
 
 
We extend the model to describe inequality in quality-adjusted life expectancy associated 
with underlying socioeconomic factors. We show the results for subgroups defined in terms 
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of the Index of Multiple Deprivation (IMD), but the method extends to any characteristic 
associated with unfair health inequality.  IMD is an area-based measure of deprivation 
incorporating seven dimensions: employment, income, education, crime, living environment 
and housing/services. Each individual in the population is associated with an IMD score 
based on their residence within one of 32,482 local super output areas (LSOAs) in England.  
We group individuals according to quintile of IMD, with IMD1 representing the most 
deprived fifth, and IMD5 representing the least deprived fifth. 
 
Using pragmatic literature review for each model input, we determine whether there is 
appropriate evidence describing variation by IMD for the following sets of inputs: (i) health 
outcomes without smoking cessation interventions (baseline health); (ii) how interventions 
change health outcomes (effectiveness), (iii) which individuals access and use interventions 
(implementation). The data are summarised in Table 1. 
 
Baseline health outcomes 
The original model sourced health-related quality of life (HRQL) weights (and the associated 
decrements from smoking) from the literature.  We characterise inequality in HRQL, 
measured through the EQ-5D instrument, using information from the Health Survey for 
England from 2012 and 2014 [26], [27]. Linear regression analysis is used to obtain average 
EQ-5D scores for smokers and former smokers by IMD quintile, controlling for respiratory 
and circulatory disease to avoid double counting the quality of life decrements of 
comorbidities included in the model. These results are reported in Table A1 (online 
appendix). Differences in mortality risk by age, sex and IMD quintile were obtained from the 
ONS (Figure A1) [28] and subsequently adjusted for smoking status. 
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Table 1 Inputs disaggregated by socioeconomic status 
   IMD quintile group    
Model input 1 2 3 4 5 Source 
Smoking population 
Number of smokers 2,457,519 1,622,583 1,448,360 927,069 773,353 [26], [27] 
Proportion of male smokers 55% 56% 56% 55% 57% [26], [27] 
EQ-5D scores 
Smokers 0.794 0.848 0.837 0.866 0.884 [26], [27] 
Former smokers 0.818 0.866 0.856 0.880 0.904 [26], [27] 
Comorbidity risk 
Relative risk of smoking-related 
illness 
1.03 0.99 1 0.95 0.84 [29] 
Odds of quit success 
All intervention types 1 1.58 1.34 1.43 1.61 [30] 
One-to-one 1 1.04 1.06 1.08 1.07 [31] 
Closed group 1 1.15 1.24 1.44 1.49 [31] 
Uptake of services 
Start2quit trial 2.39% 3.75% 3.59% 3.62% 3.83% [32] 
NHS SSS statistics 18/19 1.64% 3.17% 4.06% 4.37% 5.83% [33] 
Proportion of health opportunity cost 
Males 0.14 0.12 0.12 0.09 0.08 [34] 
Females 0.12 0.1 0.1 0.07 0.06 [34] 
Baseline quality-adjusted life expectancy 
Males 62.3 67 69.5 72.8 74.8 [35] 
Females 64.1 68.2 70.4 73.4 75.2 [35] 
Notes:  
1. Quit success odds ratios are applied such that the mean quit probability across groups is equal to mean 
value in the original model. 
2. IMD = index of multiple deprivation; SSS = Stop smoking services; *’Any service’ includes services 
outside the four listed in Table 1. 
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Inequality in the burden of smoking-related comorbidity is in part due to differences in 
prevalence of smoking between population groups.  Smoking prevalence by age, sex and 
IMD was estimated using the Health Survey for England data.  We found evidence from 
Scotland of an additional independent effect of deprivation on risk of smoking-related disease 
[29]. We assumed that the relationship by English IMD quintile was the same as that for 
Scottish IMD, and that the mean prevalence of smoking-related diseases in the existing 
model described the prevalence in the central quintile (IMD3). 
 
A number of other parameters are assumed constant over socioeconomic groups as we could 
not identify evidence detailing socioeconomic variation, such as annual healthcare cost per 
case of smoking related disease.   
 
Intervention impact 
We use estimates by Dobbie et al. [30] to account for socioeconomic variation in the 
probability of a successful quit attempt. Their analysis used NHS Stop Smoking Services data 
to estimate odds ratios for smoking cessation by IMD quintile. This did not differentiate 
between the various types of interventions and focused on the probability of quitting at four 
weeks. The use of these quit odds ratios assumes that the socioeconomic pattern observed in 
four week quit rates is reflective of the pattern in 52-week quit rates.  We found one study 
that differentiated the relationship between quit rate and socioeconomic status for different 
types of behavioural intervention. Hiscock et al. [31] examined four types of behavioural 
intervention (one-to-one, drop-in clinic, open rolling group, closed group), using a four-
category occupation-based measure of socioeconomic status (NS-SEC).  We map 11 of our 
21 interventions onto these intervention types (nine ‘one-to-one’ and two ‘closed group’) and 
9 
cross-tabulate NS-SEC and IMD quintile in the Health Survey for England to provide a link 
between these different measures.  We use Dobbie et al. for the primary analysis and examine 
a subset of interventions using Hiscock et al. in a sensitivity analysis. 
 
We found no studies describing socioeconomic variation in the relative risk reduction on all-
cause mortality or smoking-related disease from a successful quit attempt.  While we assume 
that these are the same in all groups, our characterisation of variable baseline levels of 
mortality and smoking related disease means that the absolute risk reduction is greatest in the 
most deprived groups. 
 
Service utilisation 
We estimate socioeconomic variation in service utilisation by IMD from a randomised 
controlled trial (Start2quit) of 4,300 smokers that evaluated interventions provided by NHS 
Stop Smoking Services (SSS) in England between 2012 and 2014 [32]. This covers the 
period after the funding of SSS was transferred from the NHS to local governments and 
Public Health England [36]. We calculate the proportion of smokers in each IMD quintile 
using SSS by combining the distribution of utilisation with statistics on SSS use and smoking 
prevalence for 2018/19 [33]. This indicates that utilisation is proportionally higher in less 
deprived groups but the absolute numbers of smokers utilising services is greatest in the most 
deprived groups (Table 1). 
 
A more recent distribution of service utilisation by IMD for 2018/19 can be estimated from 
national SSS statistics. This requires assigning IMD scores to individuals based on their local 
authority instead of their LSOA. We use this as a scenario analysis only for two reasons. 
First, local authorities are a much higher level of geographical aggregation (approximately 
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100 times the size of LSOAs on average) and are therefore less informative about the 
socioeconomic conditions of individuals. Second, investment decisions on SSS are now made 
by individual local authorities, which increase the possibility of a postcode lottery and larger 
variations in service utilisation. The utilisation distribution estimated from the local authority 
data, provided in Table 1, shows a steeper pro-rich gradient than in the Start2quit trial. 
 
Modelling health inequality impacts 
 
Direct health benefits 
The adapted model is run for all 21 interventions and each of the five IMD groups. This 
provides different incremental costs and QALYs from use of each intervention for smokers 
from different IMD quintiles, weighted by sex. Multiplying these ‘per smoker’ estimates by 
the number of smokers in each IMD quintile that use each intervention provides population-
level costs and QALYs. We disaggregate these QALYs by sex using the ratio of male to 
female smokers for each IMD quintile. 
 
Health opportunity costs 
NHS resource use forms the biggest component of cost changes attributed to smoking 
cessation, through changes in the amount of smoking-related disease.  Local authorities fund 
some delivery of smoking cessation services, but these implementation costs form a small 
proportion of the incremental cost.  In NICE recommendations, an intervention is regarded as 
value for money if it generates at least additional one QALY per additional £20,000 of NHS 
resources [4].  We use one QALY per £20,000 to convert total population cost into health 
opportunity cost.  The proportion of the health opportunity costs that fall on each sex and 
IMD quintile is estimated using the distribution of health benefits from marginal changes in 
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NHS expenditure in England [34].  By applying this to all resource use, NHS or otherwise, 
this assumes the same level and distribution of health opportunity cost for NHS and local 
authority public health resources.  
 
Summary intervention impact measures 
We add the net health benefit (the difference between the QALY gains and the health 
opportunity cost) by sex and IMD quintile to the baseline quality adjusted life expectancy for 
each group [35]. This yields the post-intervention distribution of quality adjusted life 
expectancy across all groups in the population. This can be compared with the baseline 
distribution to evaluate how interventions change total health and health inequality.  Change 
in total population health is described as population net health benefit in QALYs.  Absolute 
and relative inequality are measured using the slope index of inequality (SII) and the relative 
index of inequality (RII), respectively [37]. A change of -0.1 in the SII indicates that the 
difference in between the least and most healthy groups in the population has decreased by 
0.1 QALYs. The same change in RII indicates that the difference between the least and most 
healthy quintile has decreased by 10 percentage points.  
 
We compute health-related social welfare indices that integrate concern for changes in both 
total population health and health inequality. These functions contain an inequality aversion 
parameter that quantifies the strength of preference for health gains at the bottom of the 
distribution and yield a single summary measure for each distribution: equally distributed 
equivalent (EDE) health.  EDE health increases with total population health and decreases 
with enlargement of health inequality.  The functional forms we use to calculate this 
summary measure are the Kolm index [38] for absolute inequality and Atkinson index [37] 
for relative inequality.  A change in EDE can be compared against the corresponding change 
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in population net health benefit to express the value of inequality impacts in terms of 
QALYs.  When the change in EDE health is lower than change in net health benefit, the loss 
of welfare due to inequality has increased by more than the welfare gain from health 
improvement.  In the absence of evidence on the level of aversion to health inequality 
between areas defined on the basis of IMD, we use rich versus poor health inequality 
aversion parameters of α=0.15 (Kolm) and ε=10.95 (Atkinson) [40]. These values are based 
on a UK general population study, in which respondents were asked how much total 
population health they would forgo for reductions in health inequality between rich and poor 
groups. This implies that gains to the poorest fifth are weighted 6-7 times greater than those 
to the richest. 
 
Scenario and sensitivity analysis 
 
Our analysis constitutes a full distributional cost effectiveness analysis, in which the 
cumulative inequalities throughout disease and treatment course are captured (prevalence, 
access, short- and long-term health effects). We conduct sensitivity analysis to show how 
excluding information on inequalities in some of these stages of the intervention affects the 
estimated inequality impacts of the interventions. Two scenarios are explored, where (i) only 
differences in smoking prevalence are included (with mean utilisation and net health benefit) 
and (ii) differences in prevalence and utilisation are included. These scenarios correspond to 
inequality impacts that can be captured using aggregate distributional cost effectiveness 
analysis, a simplified form of analysis that can be applied without model adaptation [41], 
[42]. The difference between our base case and scenario (ii) therefore demonstrates the effect 
of conducting full DCEA compared with the aggregate approach.  
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Four further sensitivity analyses are conducted. First, we provide separate results for the 
subset of behavioural interventions for which we can specify socioeconomic variation in 
effectiveness specific to the type of intervention.  Second, we use the socioeconomic 
distribution of local authority-level service utilisation from national SSS statistics. Third, we 
vary the rate at which total costs are converted into health opportunity cost to show how the 
results change with different estimates for the marginal productivity of NHS and local 
authority public health resources. Fourth, we test the degree of inequality aversion on results 






The characteristics of the 21 interventions are reported in Table A2 (online appendix).1  The 
quit success rate at 12-months ranges from 7% for counselling to 40% for a sequence of 
varenicline, bupropion and selective serotonin reuptake inhibitors (SSRI).  Intervention costs 
(excluding over-the-counter therapies) range from £19 for brief advice to £764 for a course of 
nicotine patches and nasal spray.  
 
The change in population costs and health for each intervention are presented by IMD 
quintile in Table 2.  Summed to population-level, all interventions produce health gains and 
all but one are cost saving (Patch + Nasal Spray).  All interventions provide greater direct 
health benefits to recipients in less deprived groups. However, greater smoking prevalence in 
 
1 The different forms of counselling combined with placebo (three alternatives) and varenicline (two 
alternatives) are differentiated by number.   
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the most deprived groups mean that the interventions reduce the absolute gap in quality-
adjusted life expectancy between the most and least deprived. 
 
Impact on the distribution of health 
 
The summary measures of the intervention impacts on population health and health 
inequality are shown in Table 3. All interventions reduce absolute health inequality according 
to the SII and RII. 
 
All interventions increase EDE health when accounting for both absolute (Kolm index) and 
relative (Atkinson index) inequality. Inequality reductions from the interventions create 
health-related social welfare gains, measured by the difference between the change in net 
health benefit and change in EDE health. For the Atkinson index, the range of these gains 
were equivalent to 848 QALYs for counselling to 11,237 QALYs for patch and nasal spray. 
 
The health equity impact plane (Figure 2) shows that all the interventions lie in the northeast 
quadrant, increasing population health and reducing absolute health inequality compared to 
no smoking cessation service.  The interventions would be ranked in the same order based on 
net health benefit or EDE health. 
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IMD2 IMD3 IMD4 IMD5 
(least deprived) 
Intervention† ΔQALY ΔCost ΔQALY ΔCost ΔQALY ΔCost ΔQALY ΔCost ΔQALY ΔCost 
NRT OTC 3,052 -£6,917,329 4,916 -£12,536,763 3,534 -£10,866,434 2,397 -£7,580,235 2,501 -£7,108,358 
Placebo + counselling 1,781 -£2,339,445 2,904 -£5,642,704 2,077 -£4,880,282 1,411 -£3,494,127 1,478 -£3,344,725 
Varenicline 6,847 -£2,609,309 10,653 -£13,766,638 7,764 -£12,424,147 5,238 -£9,193,651 5,411 -£8,868,230 
Placebo + counselling 6,503 £5,410,739 10,149 -£4,967,773 7,388 -£4,844,534 4,986 -£4,261,915 5,156 -£4,492,789 
Varenicline + counselling 12,515 £1,394,028 18,526 -£16,358,331 13,768 -£15,938,888 9,219 -£12,160,750 9,389 -£11,676,392 
Placebo + counselling 7,183 -£5,173,847 11,142 -£16,884,573 8,131 -£15,149,871 5,483 -£10,996,687 5,659 -£10,480,942 
Varenicline + counselling 13,868 -£10,715,488 20,294 -£30,249,635 15,148 -£28,205,614 10,126 -£20,194,289 10,279 -£18,766,157 
Brief advice 2,101 -£3,641,208 3,415 -£7,545,233 2,446 -£6,526,479 1,661 -£4,613,773 1,738 -£4,374,674 
Varenicline + brief advice 11,024 -£13,617,599 16,530 -£30,351,061 12,223 -£27,503,658 8,201 -£19,443,962 8,382 -£18,087,399 
Self-determination intervention 3,733 £3,205,651 5,825 -£3,129,570 4,306 -£2,892,154 2,918 -£2,563,280 3,039 -£2,755,371 
Sequence (var, bup, SSRI) 19,158 -£27,633,058 26,834 -£52,036,923 20,363 -£48,612,249 13,525 -£33,757,995 13,566 -£30,588,817 
Minimal intervention (MI) 13,399 -£27,827,429 19,686 -£47,556,967 14,672 -£42,863,154 9,814 -£29,585,882 9,973 -£27,057,935 
CBT + MI 13,086 -£13,914,755 19,278 -£32,816,012 14,353 -£30,169,970 9,604 -£21,382,006 9,767 -£19,817,171 
Bupropion + CBT + MI 8,959 £343,214 13,678 -£13,450,354 10,043 -£12,568,624 6,756 -£9,575,333 6,942 -£9,316,603 
NRT + CBT + MI 13,399 -£23,583,103 19,686 -£43,152,845 14,672 -£39,098,215 9,814 -£27,161,666 9,973 -£24,918,233 
Patch and nasal spray 12,050 £17,500,254 17,910 £833,633 13,289 -£1,114,011 8,904 -£2,565,173 9,078 -£3,204,614 
Patch 4,156 -£2,399,150 6,626 -£9,611,101 4,782 -£8,478,754 3,238 -£6,232,902 3,370 -£6,036,621 
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Bupropion and lozenge 11,331 -£21,059,033 16,946 -£38,410,670 12,544 -£34,472,153 8,412 -£23,965,120 8,592 -£22,083,546 
Lozenge 5,769 -£8,514,139 9,063 -£18,376,614 6,580 -£16,188,630 4,446 -£11,456,361 4,606 -£10,789,322 
7.2mg e-cigarette 5,105 -£9,078,790 8,069 -£17,988,710 5,844 -£15,760,721 3,952 -£11,076,204 4,102 -£10,399,664 
7.2mg then 5.4mg e-cig 3,215 -£4,794,989 5,171 -£10,600,069 3,719 -£9,226,940 2,522 -£6,552,379 2,631 -£6,220,374 
Note: NRT = nicotine replacement therapy; OTC = over the counter; Var = varenicline; Bup = bupropion; SSRI = selective serotonin reuptake inhibitors; SDI = self-
determination intervention; MI = minimal intervention; CBT = cognitive behavioural therapy; QALY = quality adjusted life year 
† Three different forms of placebo + counselling and two different forms of varenicline + counselling were compared as mutually exclusive alternatives. They are numbered 
to distinguish them. 
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Table 3 Summary measures of intervention impact on distribution of health 
    Inequality reduction 





ΔSII ΔRII ΔEDEK,α ΔEDEA,ε 
NRT OTC 18,650 0.00020 0.00000 19,807 20,220 
Placebo + counselling 10,636 0.00011 0.00000 11,255 11,484 
Varenicline 38,256 0.00043 0.00000 40,702 41,554 
Placebo + counselling 34,839 0.00039 0.00000 36,957 37,715 
Varenicline + counselling  66,154 0.00078 0.00000 70,893 72,431 
Placebo + counselling 40,532 0.00046 0.00000 43,173 44,082 
Varenicline + counselling 75,123 0.00090 0.00000 80,777 82,564 
Brief advice 12,696 0.00014 0.00000 13,452 13,729 
Varenicline + brief advice 61,810 0.00072 0.00000 66,251 67,695 
Self-determination intervention 20,378 0.00022 0.00000 21,526 21,958 
Sequence (var, bup, SSRI) 103,077 0.00129 0.00001 111,741 114,314 
Minimal intervention 76,289 0.00091 0.00000 82,141 83,976 
CBT + MI 71,994 0.00086 0.00000 77,365 79,071 
Bupropion + CBT + MI 48,607 0.00056 0.00000 51,830 52,927 
NRT + CBT + MI 75,440 0.00090 0.00000 81,189 82,997 
Patch and nasal spray 60,658 0.00071 0.00000 64,797 66,174 
Patch 23,809 0.00026 0.00000 25,243 25,762 
Bupropion and lozenge 64,825 0.00076 0.00000 69,581 71,111 
Lozenge 33,730 0.00038 0.00000 35,906 36,662 
7.2mg e-cigarette 30,286 0.00034 0.00000 32,227 32,905 
7.2mg then 5.4mg e-cig 19,128 0.00021 0.00000 20,289 20,708 
Notes: 
1. ∆SII = reduction in slope index of inequality; NHB = population net health benefit; QALYs = quality 
adjusted life years; ∆RII = reduction in relative index of inequality; ∆EDEK,α = change in equally 
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distributed equivalent QALYs derived from Kolm Index; ∆EDEA,ε = change EDE QALYs derived from 
Atkinson Index 
2. NRT = nicotine replacement therapy; OTC = over the counter; Var = varenicline; Bup = bupropion; SSRI = 
selective serotonin reuptake inhibitors; SDI = self-determination intervention; MI = minimal intervention; 
CBT = cognitive behavioural therapy; QALY = quality adjusted life year 
 
Figure 2 Health equity impact plane of smoking cessation interventions 
 
Notes:  
1. QALYs = quality-adjusted life years; SII = slope index of inequality 
2. Intervention abbreviations are provided in Table A2 (online appendix) 
 
 
Sensitivity and scenario analysis 
 
Incorporating less socioeconomic variation in our example changes the direction of the 
inequality impact of nearly all interventions (Figure 3). Compared with an average base case 
SII reduction of 0.0005, including only variation in utilisation and prevalence yields an 
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average SII reduction of 0.0009.  When only prevalence variation is accounted for, all 
interventions yield yet larger SII reductions at an average of 0.0013.  
 
Figure 3 Comparison of equity impact plane locations of smoking cessation interventions 
when accounting for socioeconomic variation in all available model parameters (base case), 
prevalence and utilisation only and prevalence only  
 
Note: QALY = quality-adjusted life year; SII = slope index of inequality 
 
 
When alternative set of odds ratios are applied to eleven behavioural interventions from 
Hiscock et al., the nine mapped to one-to-one interventions showed larger reductions in 
inequality, whilst the two closed group interventions had smaller reductions. These are 
summarised in Table A3 (online appendix). For the scenario in which local authority SSS 
utilisation statistics are used, all interventions shift from inequality reducing to increasing 
(see Figure A2, online appendix). The change in the SII across interventions ranged from 
0.001 to 0.00008. 
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As the marginal productivity of the health sector increases, greater health gains can be 
generated from elsewhere in the healthcare system.  The third scenario analysis shows that as 
cost-per-forgone QALY reduces, the reduction in health inequality from cost saving 
interventions increases (see Figure A3, online appendix).  This is because marginal increases 
in expenditure on existing NHS services predominately benefit the most disadvantaged.  The 
SII reduction from the varenicline, bupropion and SSRI sequence halves from 0.0024 to 
0.0012 when the cost-per-forgone QALY increases from £2,000 to £30,000, respectively. 
The counselling intervention follows a similar trend at a greatly reduced magnitude.   
 
The effects of the same two interventions are analysed with respect to Atkinson inequality 
aversion. As aversion to inequality increases generated by the interventions increases, the 
health-related social welfare benefits increase. For the counselling intervention, EDE QALYs 
increase from 10,636 at ε=0 (no aversion) to 11,396 at ε=30. The corresponding figures for 
the varenicline, bupropion and SSRI sequence are 103,077 and 118,397, respectively. These 






Our case study demonstrates how published epidemiological and effectiveness evidence can 
be used to adapt standard decision analytic models to estimate health inequality impacts. 
Pragmatic searching and data analysis techniques identified socioeconomic variation in a 
wide range of model inputs from across the treatment pathway.   We found that despite 
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smokers from higher socioeconomic groups having a higher probability of utilising services 
and quitting upon receiving them, all interventions were expected to reduce health 
inequalities.  This was due to higher prevalence of smokers in lower socioeconomic groups.  
This distribution of direct health benefits is enhanced by the reduction in health inequality 
from cost savings, which release NHS resources that benefit the most disadvantaged more 
[34]. Our results support the NICE recommendations on the value for money of NRT, 
pharmacological and behavioural interventions [10]. 
 
Our results indicate when a full DCEA incorporating social variation in the direct health 
benefits is favourable compared to the aggregate approach, namely when the course of 
disease and treatment is likely to have countervailing inequality impacts (e.g. pro-rich quit 
success vs. pro-poor prevalence) and when there is a strong behavioural component 
determining the treatment effect (quit success in the case of smoking). Our full DCEA finds 
the magnitude of the inequality impacts were 1.6 times greater when only differences in 
prevalence and service utilisation are accounted for and 2.4 times larger when prevalence 
differences only are included.  
 
The scenario results demonstrate the value of targeted provision of smoking cessation 
services that reduce socioeconomic variation in service uptake, which in our analysis higher 
in the least deprived areas compared with the most deprived (3.83% vs 2.39%) [43]. 
Evidence suggests that these differences have increased since SSS funding was transferred 
from the NHS to local authorities in England in 2013 as total utilisation as steadily as 
decreased [44], [45]. Improving the implementation of smoking cessation interventions 
therefore represents a potentially fruitful area of future research [46], [47].   
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Other studies have investigated the differential impact of smoking cessation policies between 
socioeconomic groups in settings outside the UK [48], [49].  However, these studies present 
results in a dashboard of effects across socioeconomic groups, and do not attempt to 
summarise impact on health inequality nor consider the distribution of health opportunity 
cost.  The benefit of our approach is that it explicitly estimates the net impact on health 
inequality and can help decision makers navigate trade-offs between population health 
benefit and health inequality impacts, which health-related social welfare analysis can do 
quantitatively.  The case study results show that the inequality reductions of the smoking 
cessation interventions account for up to 10% of the overall social value in terms of EDE 




Due to the resource constraint of this pilot study we use pragmatic reviews to identify 
relevant evidence.  Socioeconomic variation in smoking behaviours and outcomes are well-
researched, and evidence in other health and disease areas might be more limited [50], [51].  
We made additional assumptions on top of those in the original economic evaluation for 
NICE.  Where we do not find evidence describing how an input varies with IMD, we apply 
the average value to all groups, i.e. assuming no inequality.  However, the relative risk 
reduction of all-cause mortality might be greater in heavier smokers, who may be more 
concentrated in lower socioeconomic groups [9].  The HRQL benefits of smoking cessation, 
whilst well established in the literature [52], do not control for all confounding factors that 
may be associated with socioeconomic status, such as stress level or BMI. Where these 
factors are more common amongst lower socioeconomic groups, this will lead to an 
overestimate of health inequality reductions (and vice versa).  Assuming that the 
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socioeconomic variation in quit success at four weeks is maintained at 52 weeks may 
underestimate inequality if we expect more relapse in lower socioeconomic groups.  We also 
assume that service interventions do not alter the relative odds of quit success between 
socioeconomic groups, as we could not find information on how the ‘natural’ background 
quit rate varied by IMD. 
 
While we assess differences in effectiveness and uptake between socioeconomic groups, we 
lack sufficient evidence on how this varies by type of intervention.  Likewise, data on uptake 
are only available for broad intervention type and are contaminated by systematic variation in 
the availability of services in each local authority. 
 
Our analysis assumes the same marginal productivity for NHS and local authority public 
health resources.  In this particular application is may be reasonable given the predominance 
of health sector costs in determining the overall cost impact.  Conclusions about interventions 
providing value for money were not sensitive to alternative assumptions about the size and 
distribution of the health opportunity costs.  However, for interventions that impose greater 
impacts on budgets outside the health sector (i.e. public health or social care), potential 
differences in the size and distribution of health opportunity costs should be reflected. 
 
The inequality aversion parameter we used is estimated for inequalities in healthy life 
expectancy between “rich” and “poor” groups IMD groups.  Identifying social values for 
health inequality reduction compared to increases in population health is a complicated 
process.  However, the level of health inequality aversion did not alter the rank order of the 





We show how that cost-effectiveness models can be extended to conduct a full DCEA within 
the resource constraints of a national guideline development. This adaptation can be 
influential in determining the direction and magnitude of the inequality compared with more 
simplified approaches that account for differences in utilisation or prevalence only. The 
analysis can also help to inform how DCEA could be incorporated into existing formal health 
technology assessment processes given analysts may have to be selective about which 
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